{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:08:47Z","timestamp":1760044127282},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.2169\/internalmedicine.0403-17","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T22:25:20Z","timestamp":1528237520000},"page":"3213-3216","source":"Crossref","is-referenced-by-count":7,"title":["Valacyclovir-induced Neurotoxicity in a Patient with a Preserved Renal Function"],"prefix":"10.2169","volume":"57","author":[{"given":"Takashi","family":"Yoshimura","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, Matsushita Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Matsushita Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Shirota","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Matsushita Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Matsushita Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Matsushita Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Matsushita Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 44: S1-26, 2007.","DOI":"10.1086\/510206"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Wassilew SW, Wutzler P; Brivddin Herpes Zoster Study Group. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 59: 49-56, 2003.","DOI":"10.1016\/S0166-3542(03)00065-2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 39: 1546-1553, 1995.","DOI":"10.1128\/AAC.39.7.1546"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Blum MR, Liao SH, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med 73: 186-192, 1982.","DOI":"10.1016\/0002-9343(82)90088-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Carvounis CP, Nisar S, Guro-Razuman S. Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int 62: 2223-2229, 2002.","DOI":"10.1046\/j.1523-1755.2002.00683.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Huguenel C, Felton D, Bruccoleri R, Salhanick S. Case files of the Harvard medical toxicology fellowship: valacyclovir neurotoxicity and unintentional overdose. J Med Toxicol 11: 132-136, 2015.","DOI":"10.1007\/s13181-014-0457-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lycke J, Andersen O, Svennerholm B, Appelgren L, Dahl\u00f6f C. Acyclovir concentrations in serum and cerebrospinal fluid at steady state. J Antimicrob Chemother 24: 947-954, 1989.","DOI":"10.1093\/jac\/24.6.947"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jemsek J, Greenberg SB, Taber L, Harvey D, Gershon A. Couch RB. Herpes zoster-associated encephalitis: clinicopathologic report of 12 cases and review of the literature. Medicine (Baltimore) 62: 81-97, 1983.","DOI":"10.1097\/00005792-198303000-00002"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Adair JC, Gold M, Bond RE. Acyclovir neurotoxicity: clinical experience and review of the literature. South Med J 87: 1227-1231, 1994.","DOI":"10.1097\/00007611-199412000-00006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hughes BA, Kimmel DW, Aksamit AJ. Herpes zoster-associated meningoencephalitis in patients with systemic cancer. Mayo Clin Proc 68: 652-655, 1993.","DOI":"10.1016\/S0025-6196(12)60600-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1: 417-422, 1995.","DOI":"10.1038\/nm0595-417"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 20: 289-302, 2003.","DOI":"10.2165\/00002512-200320040-00005"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol 72: 381-393, 2011.","DOI":"10.1111\/j.1365-2125.2011.03991.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Akahane K, Tsutomi Y, Kimura Y, Kitano Y. Levofloxacin, an optical isomer of ofloxacin, has attenuated epileptogenic activity in mice and inhibitory potency in GABA receptor binding. Chemotherapy 40: 412-417, 1994.","DOI":"10.1159\/000239301"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Akahane K, Sekiguchi M, Une T, Osada Y. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother 33: 1704-1708, 1989.","DOI":"10.1128\/AAC.33.10.1704"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47: 677-700, 1994.","DOI":"10.2165\/00003495-199447040-00008"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Czock D, H\u00fcsig-Linde C, Langhoff A, et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol 1: 1263-1268, 2006.","DOI":"10.2215\/CJN.01840506"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Asahi T, Tsutsui M, Wakasugi M, et al. Valacyclovir neurotoxicity: clinical experience and review of the literature. Eur J Neurol 16: 457-460, 2009.","DOI":"10.1111\/j.1468-1331.2008.02527.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 28: 281-290, 1995.","DOI":"10.1016\/0166-3542(95)00066-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lam NN, Weir MA, Yao Z, et al. Risk of acute kidney injury from oral acyclovir: a population-based study. Am J Kidney Dis 61: 723-729, 2013.","DOI":"10.1053\/j.ajkd.2012.12.008"},{"key":"21","unstructured":"21. Valtrex (Valacyclovir Hydrochloride) Caplets - FDA [Internet]. [cited 2018 Jan. 15]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020487s014lbl.pdf"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 39: 2759-2764, 1995.","DOI":"10.1128\/AAC.39.12.2759"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Oxman MN, Levin MJ, Johnson GR, et al. ; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352: 2271-2284, 2005.","DOI":"10.1056\/NEJMoa051016"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. James SH, Larson KB, Acosta EP, Prichard MN. Helicase-primase as a target of new therapies for herpes simplex virus infections. Clin Pharmacol Ther 97: 66-78, 2015.","DOI":"10.1002\/cpt.3"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kawashima M, Nemoto O, Honda M, et al. ; study investigators. Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study. J Dermatol 44: 1219-1227, 2017.","DOI":"10.1111\/1346-8138.13948"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/21\/57_0403-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T05:16:56Z","timestamp":1541222216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/21\/57_0403-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":25,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0403-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,1]]}}}